R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study

✍ Scribed by Antonio Rueda; Pilar Sabin; Juli Rifá; Marta Llanos; José Gómez-Codina; Francisco Lobo; Ramón García; Joaquin Herrero; Mariano Provencio; Carlos Jara

• Publisher: John Wiley and Sons
• Year: 2008
• Tongue: English
• Weight: 116 KB
• Volume: 26
• Category: Article
• ISSN: 0278-0232
• DOI: 10.1002/hon.829

✦ Synopsis

Abstract

Several studies have shown that adding rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or reducing the interval between chemotherapy cycles from 3 weeks to 2 weeks improves survival in patients with diffuse large B‐cell lymphoma (DLBCL). These studies prompted our group (GOTEL) to evaluate prospectively in a pilot study the feasibility and efficacy of R‐CHOP‐14 in patients with DLBCL. Patients (<70 years) with stage II bulky or stage III or IV DLBCL and no significant comorbidities were included in the study. Rituximab was administered on day 1 before chemotherapy. R‐CHOP was given every 14 days. All patients received filgrastim (5 µg/kg) from days 4 to 10. From May 2002 to August 2004, 80 patients were recruited. Median age was 53 years and 58 patients were <60 years. According to the age‐adjusted international prognostic index (aaIPI), 13 patients (16%) had low‐risk disease, 31 (39%) low‐to‐intermediate risk, 27 (34%) high‐to‐intermediate risk and 9 (11%) high‐risk disease. Grade 3–4 neutropenia was observed in 15 patients (17.5%) and grade 3–4 infections in 13 patients (16%). After therapy, 58 patients (73%) achieved CR‐CRu (95% CI: 55–90%). With a median follow‐up of 26 months, progression‐free survival (PFS) and overall survival (OS) at 30 months were 72% and 86%, respectively. Administration of R‐CHOP‐14 is feasible and effective in patients <70 years. Copyright © 2007 John Wiley & Sons, Ltd.